Bakır Metabolizması Bozuklukları
Özet
Bakır, hücresel süreçler ve enzim fonksiyonları için kritik bir metal olup, dengesi ATP7A ve ATP7B gibi proteinlerle hassas bir şekilde korunur. Bu homeostatik mekanizmalardaki genetik bozukluklar, özellikle karaciğer ve beyinde bakır birikimine veya eksikliğine yol açarak Wilson ve Menkes gibi ciddi klinik tablolara neden olur. Tanı süreci, klinik bulguların biyokimyasal analizler ve genetik testlerle desteklenmesine dayanır. Tedavi, hastalığın tipine göre şelasyon ajanları veya bakır replasmanı gibi, bakır seviyelerini normale döndürmeyi hedefleyen yaklaşımları içerir.
Copper is an essential metal critical for cellular processes, with its homeostasis strictly managed by specific transport proteins like ATP7A and ATP7B. Genetic mutations affecting these mechanisms lead to abnormal copper accumulation or deficiency, causing serious clinical conditions such as Wilson’s and Menkes diseases that primarily target the liver and brain. Diagnosing these disorders requires a combination of clinical evaluation, biochemical markers, and molecular genetic testing. Treatment approaches are customized to the specific pathology, utilizing either copper chelation or replacement therapies to restore metabolic balance.
Referanslar
Kaler SG. Inborn errors of copper metabolism. Dulac O, Lassonde M, Sarnat HB, Editors. Handbook of Clinical Neurology, Vol. 113 (3rd series) Pediatric Neurology Part III. USA: Elsevier B.V; 2013. p. 1746-1753.
Aydın F, Ulusoy Ş, Mocan Z, Mocan H, Uzun Y. Eser element olarak bakır ve ilgili klinik durumlar. SSK Tepecik Hast Derg 1992; 2 (3) : 260 – 4
Gürkan Ö, Eğritaş G, Yüce FA. Çocuklarda Wilson Hastalığı Rehberi. Türk Çocuk Gastroenteroloji, Hepatoloji ve Beslenme Derneği. Nisan 2019 https://www.pedgastro.org/doc/rehber/Wilson%20Rehberi.pdf (08.02.2021)
Inesi G. Molecular features of copper binding proteins involved in copper homeostasis. IUBMB Life 2017 Apr;69(4):211-217. doi: 10.1002/iub.1590.
Lutsenko S, Barnes NL, Bartee MY, Dmitriev OY. Function and regulation of human copper-transporting ATPases. 2007 Physiol. Rev. 87, 1011–1046.
Crisponi G, Nurchi VM, Gerosa C, Fanni D, Nemolato S, Faa G. Copper uptake end trafficking in the brain. Linert W, Kozlowski H, Editors. Metal Ions in Neurological Systems. Wien: Springer-Verlag; 2012. p. 47-63.
Faa G, Gerosa C, Castagnola M. MEDNIK syndrome: a new entry in the spectrum of inborn errors of copper metabolism. J Pediatr Neonat Individual Med. 2020;9(2):e090202. doi: 10.7363/090202.
Crisponi G, Nurchi VM, Fanni D, Gerosa C, Nemolato S, Faa G. Copper-related diseases: from chemistry to molecular pathology. Coord Chem Rev. 2010;254:876-89.
Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. Lancet Neurol 2015 Jan;14(1):103-13. doi: 10.1016/S1474-4422(14)70190-5.
Girard M, Poujois A, Fabre M, et al. CCDC115-CDG: a new rare and misleading inherited cause of liver disease. Mol Genet Metab 2018 Jul;124(3):228-235. doi: 10.1016/j.ymgme.2018.05.002.
Wilson SAK. Progresive lenticular degeneration: familial nervous disease associated with cirrhosis of the liver. Brain 1912;34:295-507.
Walshe JM. The story of penicillamine: a difficult birth. Mov Disord 2003. 18;8: 853–859.
Bull PC, Thomas GR, Rommens JM et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993 Dec;5(4):327-37. doi: 10.1038/ng1293-327.
Cooper, D. N. et al. The Human Gene Mutation Database. QIAGEN http://www.hgmd.cf.ac.uk/ac/ index.php (2018).
Członkowska A, Litwin T, Dusek P, at all. Wilson disease. Nat Rev Dis Primers. 2018 Sep 6;4(1):21. doi: 10.1038/s41572-018-0018-3.2.
Frank Y, Ashwal S. Neurologic Disorders Associated with Gastrointestinal Diseases and Nutritional Deficiencies, Hepatolenticular Degeneration: Wilson’s Disease. Swaiman KF, Aswal S, Ferriero DM, Schor NF, editors. Principle and practice pediatric neurology. fifth edition. USA: Saunders, Elsevier Inc; 2012. p. 1839-41.
Letelier ME, Sánchez JS, Peredo SL, Cortés TJ, Aracena PP. Mechanisms underlying iron and copper ions toxicity in biological systems: pro-oxidant activity and protein-binding effects. Chem Biol Interact. 2010 Oct 6;188(1):220-7. doi: 10.1016/j.cbi.2010.06.013.
Borchard S, Bork F, Rieder T, et all. Toxicol In Vitro. 2018 Sep;51:11-22. doi: 10.1016/j.tiv.2018.04.012.
European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol. 2012 Mar;56(3):671-85. doi: 10.1016/j.jhep.2011.11.007.
Lang PA, Schenck M, Nicolay JP, et all. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med. 2007 Feb;13(2):164-70. doi: 10.1038/nm1539.
Scheiber IF, Dringen R. Copper-treatment increases the cellular GSH content and accelerates GSH export from cultured rat astrocytes. Neurosci Lett. 2011 Jul 1;498(1):42-6. doi: 10.1016/j.neulet.2011.04.058.
Bertrand E, Lewandowska E, Szpak GM, et all. Neuropathological analysis of pathological forms of astroglia in Wilson's disease. Folia Neuropathol. 2001;39(2):73-9.
Dusek P, Bahn E, Litwin T, Jabłonka-SK, et al. Brain iron accumulation in Wilson disease: a post mortem 7 Tesla MRI - histopathological study. Neuropathol Appl Neurobiol. 2017 Oct;43(6):514-532. doi: 10.1111/nan.12341
Svetel M, Kozić D, Stefanova E, Semnic R, Dragasevic N, Kostic VS. Dystonia in Wilson's disease. Mov Disord. 2001 Jul;16(4):719-23. doi: 10.1002/mds.1118.
Kaler SG. Wilson disease. L Goldman, D Ausiello, editors. Cecil’s Textbook of Medicine. 23rd edn. Saunders, Philadelphia, ch: 2008. p. 1593–1595.
Yalçınkaya C. Bazal gangliyonların dejeneratif hastalıkları. Gökçay E, Sönmez M, Topaloğlu H, Tekgül H, Gürer Y, editörler. 2. Baskı. Çocuk Nörolojisi. Ankara: 2010. p.189-190.
Attri S, Sharma N, Jahagirdar S, Ram TB, Prasad R. Erythrocyte metabolism and antioxidant status of patients with Wilson disease with hemolytic anemia. Pediatr Res. 2006 Apr;59(4 Pt 1):593-7. doi: 10.1203/01.pdr.0000203098.77573.39
Akil M, Brewer GJ. Psychiatric and behavioral abnormalities in Wilson's disease. Adv Neurol. 1995;65:171-8.
Lucato LT, Concepción GM, Barbosa ER, et al. Proton MR spectroscopy in Wilson disease: analysis of 36 cases. AJNR Am J Neuroradiol. 2005 May;26(5):1066-71.
Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003;23:139-42.
Koppikar S, Dhawan A. Evaluation of the scoring system for the diagnosis of Wilson’s disease in children. Liver Int 2005;25:680-1.
Brewer G J. Practical recommendations and new therapies for Wilson's disease. Drugs. 1995 Aug;50(2):240-9. doi: 10.2165/00003495-199550020-00004.
Horn N, Møller LB, Nurchi VM, Aaseth J. Chelating principles in Menkes and Wilson diseases: Choosing the right compounds in the right combinations at the right time. J Inorg Biochem. 2019;190:98-112.
Taylor RM, Chen Y, Dhawan A. Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King’s College Hospital and review of the literature. Eur J Pediatr 2009;168:1061-8.
Socha P, Janczyk W, Dhawan A, et al. Wilson's disease in children: A position paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:334-44.
Hermann W. Classification and differential diagnosis of Wilson’s disease. Ann Transl Med 2019;7(Suppl 2):S63. doi: 10.21037/atm.2019.02.07
Kaler SG. Metabolic and molecular bases of Menkes disease and occipital horn syndrome. Pediatr Dev Pathol. Jan-Feb 1998;1(1):85-98. doi: 10.1007/s100249900011.
Menkes JH, Alter M, Steigleder GK, Weakley DR, Sung JH. A sex-linked recessive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration. Pediatrics. 1962 May;29:764-79.
Danks DM, Campbell PE, Walker-Smith J, et al. Menkes' kinky-hair syndrome. Lancet. 1972 May 20;1(7760):1100-2. doi: 10.1016/s0140-6736(72)91433-x.
Tümer Z, Møller LB, Horn N. Screening of 383 unrelated patients affected with Menkes disease and finding of 57 gross deletions in ATP7A. Hum Mutat. 2003 Dec;22(6):457-64. doi: 10.1002/humu.10287.
Tønnesen T, Kleijer WJ, Horn N. Incidence of Menkes disease. Hum Genet. 1991 Feb;86(4):408-10. doi: 10.1007/BF00201846.
Axelrod FB. Systemic and Autonomic Nervous System Diseases. Swaiman KF, Aswal S, Ferriero DM, Schor NF, editors. Principle and practice pediatric neurology. fifth edition. USA: Saunders, Elsevier Inc; 2012. p. 1716.
Prohaska JR, Bailey WR, Lear PM. Copper deficiency alters rat peptidylglycine alpha-amidating monooxygenase activity. J Nutr. 1995 Jun;125(6):1447-54. doi: 10.1093/jn/125.6.1447.
Rossi L, De Martino A, Marchese E, Piccirilli S, Rotilio G, Ciriolo MR. Neurodegeneration in the animal model of Menkes' disease involves Bcl-2-linked apoptosis. Neuroscience. 2001;103(1):181-8. doi: 10.1016/s0306-4522(00)00562-5.
Boustany RN, El-Bitar MK. Degenerative Disorders Primarily of Gray Matter. Swaiman KF, Aswal S, Ferriero DM, Schor NF, editors. Principle and practice pediatric neurology. fifth edition. USA: Saunders, Elsevier Inc; 2012. p. 525-529.
Moore CM, Howell RR. Ectodermal manifestations in Menkes disease. Clin Genet. 1985 Dec;28(6):532-40. doi: 10.1111/j.1399-0004.1985.tb00422.x.
Balestracci A, Caletti MG, Missoni M. A case of Menkes' disease with nephrocalcinosis and chronic renal failure. Pediatr Nephrol. 2009 Jun;24(6):1255-6. doi: 10.1007/s00467-008-1104-7.
Gasch AT, Caruso RC, Kaler SG, Kaiser-Kupfer M. Menkes' syndrome: ophthalmic findings. Ophthalmology. 2002 Aug;109(8):1477-83. doi: 10.1016/s0161-6420(02)01095-3.
Vairo FPE, Chwal BC, Perini S, et al. A systematic review and evidence-based guideline for diagnosis and treatment of Menkes disease. Mol Genet Metab. 2019 Jan;126(1):6-13. doi: 10.1016/j.ymgme.2018.12.005.
Tønnesen T, Horn N. Prenatal and postnatal diagnosis of Menkes disease, an inherited disorder of copper metabolism. J Inherit Metab Dis. 1989;12 Suppl 1:207-14. doi: 10.1007/BF01799296.
Verrotti A, Carelli A, Coppola G. Epilepsy in children with Menkes disease: a systematic review of literatüre. J Child Neurol. 2014 Dec;29(12):1757-64. doi: 10.1177/0883073814541469.
Kaler SG. Neurodevelopment and brain growth in classic Menkes disease is influenced by age and symptomatology at initiation of copper treatment. J Trace Elem Med Biol. 2014 Oct;28(4):427-30. doi: 10.1016/j.jtemb.2014.08.008.
Beyens A, Van Meensel K, Pottie L, et al. Defining the clinical, molecular and ultrastructural characteristics in Occipital Horn Syndrome:two new cases and review of the literatüre. Genes (Basel). 2019 Jul 12;10(7):528. doi: 10.3390/genes10070528.
Tsukahara M, Imaizumi K, Kawai S, Kajii T. Occipital horn syndrome: report of a patient and review of the literature. Clin Genet 1994: 45: 32-35.
Tümer Z, Møller LB. Menkes disease. Eur J Hum Genet. 2010 May;18(5):511-8. doi: 10.1038/ejhg.2009.187.
Kaler SG, Gallo LK, Proud VK, et al. Occipital horn syndrome and a mild Menkes phenotype associated with splice site mutations at the MNK locus. Nat Genet. 1994 Oct;8(2):195-202. doi: 10.1038/ng1094-195.
Tümer Z. An Overview and Update of ATP7A Mutations Leading to Menkes Disease and Occipital Horn Syndrome. Hum Mutat. 2013 Mar;34(3):417-29. doi: 10.1002/humu.22266.
Kennerson ML, Nicholson GA, Kaler SG, et al. Missense mutations in the copper transporter gene ATP7A cause X-linked distal hereditary motor neuropathy. Am J Hum Genet. 2010 Mar 12;86(3):343-52. doi: 10.1016/j.ajhg.2010.01.027.
Yi L, Kaler S. ATP7A trafficking and mechanisms underlying the distal motor neuropathy induced by mutations in ATP7A. Ann N Y Acad Sci. 2014 May;1314(1):49-54. doi: 10.1111/nyas.12427.
Møller LB. Small amounts of functional ATP7A protein permit mild phenotype. J Trace Elem Med Biol. 2015;31:173-7. doi: 10.1016/j.jtemb.2014.07.022.
Gualandi F, Sette E, Fortunato F, et al. Report of a novel ATP7A mutation causing distal motor neuropathy. Neuromuscul Disord. 2019;29(10):776-85.
Huppke P, Brendel C, Kalscheuer V, et al. Mutations in SLC33A1 cause a lethal autosomal-recessive disorder with congenital cataracts, hearing loss, and low serum copper and ceruloplasmin. Am J Hum Genet 2012; 90: 61–68.
Chiplunkar S, Bindu PS, Nagappa M, et al. Huppke-Brendel syndrome in a seven month old boy with a novel 2-bp deletion in SLC33A1. Metabolic Brain Disease 2016;31:1195-8.
Bindu PS, Chiplunkar S, Vandana VP, et al. HuppkeBrendel Syndrome. 2019 Jun 13. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. https://www.ncbi.nlm.nih.gov/books/
Huppke P, Brendel C, Korenke GC, et al. Molecular and biochemical characterization of a unique mutation in CCS, the human copper chaperone to superoxide dismutase. Hum Mutat 2012;33:1207-15.
Faa G, Gerosa C, Castagnola M. MEDNIK syndrome: a new entry in the spectrum of inborn errors of copper metabolism. J Pediatr Neonat Individual Med. 2020;9(2):e090202. doi: 10.7363/090202.
Beare JM, Nevin NC, Froggatt P, Kernohan DC, Allen IV. Atypical erythrokeratoderma with deafness, physical retardation and peripheral neuropathy. Br J Dermatol. 1972;187:308-14.
Saba TG, Montpetit A, Verner A, Rioux P, Hudson TJ, Drouin R, Drouin CA. An atypical form of erythrokeratodermia variabilis maps to chromosome 7q22. Hum Genet. 2005;116(3): 167-71.
Montpetit A, Coté S, Brustein E, et al. Disruption of AP1S1, causing a novel neurocutaneous syndrome, perturbs development of the skin and spinal cord. PLoS Genet. 2008 Dec;4(12):e1000296. doi: 10.1371/journal.pgen.1000296
Martinelli D, Travaglini L, Drouin CA, et al. MEDNIK syndrome: a novel defect of copper metabolism treatable by zinc acetate therapy. Brain. 2013;136: 872-81.
Incecik F, Bisgin A, Yılmaz M. MEDNIK syndrome with a frame shift causing mutation in AP1S1 gene and literature review of the clinical features. Metab Brain Dis. 2018;33(6):2065-8.
Incecık F, Herguner MO, Ozbek MN, et al. Neuro-ichthyotic Syndromes: A Case Series. J Pediatr Neurosci. Jan-Mar 2018;13(1):34-38. doi: 10.4103/JPN.JPN_54_17.
Martinelli D, Dionisi-Vici C. AP1S1 defect causing MEDNIK syndrome: a new adaptinopathy associated with defective copper metabolism. Ann N Y Acad Sci. 2014;1314:55-63
Alsaif HS, Al-Owain M, Barrios-Llerena ME, et al. Homozygous Loss-of-Function Mutations in AP1B1, Encoding Beta-1 Subunit of Adaptor-Related Protein Complex 1, Cause MEDNIK-like Syndrome. Am J Hum Genet. 2019;105(5):1016-22.
Boyden LM, Atzmony L, Hamilton C, et al. Recessive Mutations in AP1B1 Cause Ichthyosis, Deafness, and Photophobia. Am J Hum Genet. 2019;105(5):1023-1029.
Ito Y, Takeichi T, Igari S, et al. MEDNIK-like syndrome due to compound
Eur Acad Dermatol Venereol. 2020 Dec 22. doi: 10.1111/jdv.17098.
Rizzo WB, Jenkens SM, Boucher P. Recognition and Diagnosis of Neuro-Ichthyotic Syndromes. Semin Neurol. 2012; 32(1): 75–84. doi:10.1055/s-0032-1306390.
